12 Dec, 11 | by BMJ Group
Jennifer Quint (Thorax’s journal club editor) talks to Dr John Matthews (Genentech) about his New England Journal of Medicine published study into whether lebrikizumab, an interleukin-13 monoclonal antibody, can improve asthma control.
Dr Matthews explains the proposed mechanism behind the treatment and how they found it increased FEV1 in adults for whom inhaled glucocorticoids didn’t control their asthma - especially in those with high periostin levels.
Dr Matthews was involved in the Milly trial. This podcast is intended for healthcare professionals only.